NIKKEI 225
38,236.07 -37.98 (-0.10%) HANG SENG
18,207.13 +444.10 (+2.50%) CRUDE OIL
79.14 +0.19 (+0.24%) GOLD FUTURES
2,314.30 +4.70 (+0.20%) DOW
38,225.66 +322.37 (+0.85%) Bitcoin GBP
47,290.05 +1,098.74 (+2.38%)
PTN Oct 2024 2.500 call
| Previous close | 0.3000 |
| Open | 0.4500 |
| Bid | 0.4500 |
| Ask | 0.6500 |
| Strike | 2.50 |
| Expiry date | 2024-10-18 |
| Day's range | 0.4500 - 0.4500 |
| Contract range | N/A |
| Volume | |
| Open interest | 68 |
PR NewswirePalatin Announces FDA Clearance of IND Application for the Co-Administration of Bremelanotide with Tirzepatide (GLP-1) for the Treatment of Obesity
Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today announced that the U.S. Food and Drug Administration (FDA) has completed its 30-day review of the investigational new drug (IND) application for the use of bremelanotide, a melanocortin receptor 4 agonist (MCR4), for the treatment of obesity. The Company is cleared to begin enrollment in a Phase 2
- PR Newswire
Palatin to Host Virtual KOL Event "Beyond GLPs: The Multiple Roles for Novel Melanocortin Receptor 4 Agonists in Treating Obesity and Weight Loss Maintenance" on May 8, 2024
Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today announced it will host a virtual KOL event on Wednesday, May 8, 2024 at 10:00 AM ET. To register, click here.
Insider Monkey10 Micro-Cap Healthcare Stocks Insiders Are Buying
In this article, we will take a detailed look at the 10 Micro-Cap Healthcare Stocks Insiders Are Buying. For a quick overview of such stocks, read our article 5 Micro-Cap Healthcare Stocks Insiders Are Buying. Investors have always been interested in the connection between insider buying and stock returns. Over the past several years there’s been a huge influx […]
